enGene Holdings Inc. (NASDAQ:ENGN) Given Average Rating of "Buy" by Analysts

Key Points

• enGene Holdings Inc. has received a consensus rating of "Buy" from analysts, with eight firms covering the stock, including one strong buy recommendation.
• Shares of enGene have increased by 3.6% and currently trade at approximately $5.18, despite a 12-month price objective of $23.2857 set by analysts.
• The company recently reported a quarterly EPS of ($0.51), missing expectations and predicts a -1.56 EPS for the current year.

Shares of enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) have been assigned a consensus rating of "Buy" from the eight ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $23.2857.

enGene Trading Up 3.6%

Shares of ENGN stock opened at $5.18 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 12.66 and a current ratio of 12.66. enGene has a 1 year low of $2.65 and a 1 year high of $11.00. The stock has a fifty day moving average of $3.92 and a two-hundred day moving average of $4.13. The firm has a market capitalization of $264.72 million, a PE ratio of -3.14 and a beta of -0.39.

enGene (NASDAQ:ENGN - Get Free Report) last announced its quarterly earnings results on Tuesday, June 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.03). As a group, research analysts expect that enGene will post -1.56 EPS for the current year.

Institutional Trading of enGene

Several institutional investors have recently modified their holdings of the company. Paloma Partners Management Co acquired a new stake in shares of enGene in the second quarter valued at $38,000. Affinity Asset Advisors LLC acquired a new stake in shares of enGene in the second quarter valued at $280,000. Cresset Asset Management LLC acquired a new stake in shares of enGene in the second quarter valued at $36,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of enGene by 2.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company's stock valued at $7,041,000 after buying an additional 41,874 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of enGene in the first quarter valued at $107,000. Institutional investors and hedge funds own 64.16% of the company's stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.